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Nuclear factor-jB and inhibitor of jB kinase pathways in oncogenic
initiation and progression
DS Basse`res and AS Baldwin
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Abundant data support a key role for the transcription
factor nuclear factor-jB (NF-jB) signaling pathway in
controlling the initiation and progression of human cancer.
NF-jB and associated regulatory proteins such as IjB
kinase (IKK) are activated downstream of many onco-
proteins and there is much evidence for the activation of
NF-jB-dependent target genes in a variety of solid tumors
and hematologic malignancies. This review focuses on the
mechanisms by which the NF-jB pathway is activated in
cancer and on the oncogenic functions controlled by
activated NF-jB. Additionally, the effects of NF-jB
activation in tumors relative to cancer therapy are also
discussed.
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Regulation of NF-jB
NF-kB is a dimeric transcription factor formed by
members of a family of proteins that share a conserved
N-terminal dimerization/DNA-binding region desig-
nated the Rel homology domain. In mammalian cells,
the NF-kB family is composed of ﬁve members:
RelA(p65), RelB, c-Rel, p50/p105 (NF-kB1) and p52/
p100 (NF-kB2) (Gilmore, 2006). The ability of these ﬁve
members to form a variety of homo- and heterodimers
and, ultimately, to differentially control gene expression
is regulated by signals elicited by bacterial products,
cytokines, viral expression, growth factors and stress
stimuli (reviewed by Hayden and Ghosh, 2004).
Based on their overall structures and processing, the
NF-kB family can be further subdivided into the
‘NF-kB’ proteins (p50/p105, p52/p100) and the ‘Rel’
proteins (RelA, RelB, c-Rel). The NF-kB proteins, p50
and p52, are produced by proteolytic removal of
C-terminal sequences from larger precursor proteins
(p105 and p100, respectively). In contrast, RelA, RelB
and c-Rel contain C-terminal transactivation domains,
which are not present in p50 and p52. Nonetheless, the
p50 and p52 subunits provide DNA-binding speciﬁcity
by forming heterodimers with other NF-kB subunits and
are known to contribute to gene expression. Speciﬁcally,
p50/p50 or p52/p52 homodimers can positively and
negatively regulate expression of NF-kB target genes by
recruiting co-activators or co-repressors. For instance,
p50 appears to both positively and negatively regulate
the expression of the KAI1 metastasis suppressor gene
(Kim et al., 2005a). In this case, the oncoprotein b-
catenin simultaneously displaces the Tip60 co-activator
from the p50 complex in the KalI promoter and induces
recruitment of transcriptional co-repressors, thereby
converting the p50 transcriptionally active complex into
a repressive complex (Kim et al., 2005a).
Under most basal conditions, NF-kB complexes are
maintained in an inactive form primarily through
interactions with the inhibitor of kB (IkB) family of
proteins. The IkB family has several known members,
including IkBa, IkBb, IkBe, Bcl-3, p100 and p105, all of
which contain ankyrin-like repeats that mediate binding
to and inhibition of NF-kB. Generally, the IkB proteins
sequester the interacting NF-kB dimeric complexes in the
cytoplasm, and therefore the ability of NF-kB to bind
DNA and regulate gene expression is blocked. It should
be noted that Bcl-3 is unusual in that it does not induce
cytoplasmic retention, but rather positively regulates gene
expression by acting as a transcriptional co-activator for
NF-kB p50 and p52 homodimers in the nucleus on DNA
(Fujita et al., 1993; Westerheide et al., 2001).
Most stimuli activate NF-kB by modulating the
activity of the IkB kinase (IKK) complex, which is
comprised of three subunits: IKKa, IKKb and NF-kB
essential modulator (NEMO) (IKKg). IKKa and IKKb
are both catalytic kinases, whereas NEMO acts as a
regulatory scaffold component for the IKK complex.
Upon stimulation, the IKK complex phosphorylates the
IkB proteins, which then undergo rapid ubiquitination
and proteasome-mediated degradation, which culmi-
nates in the release of the NF-kB complexes from their
inhibitory interaction (see Scheidereit, 2006). The
released complexes then accumulate in the nucleus,
where they bind to target DNA sequences and regulate
the expression of genes involved in the immune
response, cell growth control and the regulation of cell
survival (Hayden and Ghosh, 2004).
There are, however, two distinct pathways that lead
to the activation of NF-kB – the canonical and the
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non-canonical pathways. These pathways are activated
by often distinct stimuli, require different IKK com-
plexes, and induce different NF-kB complexes and
different target genes (see Scheidereit, 2006). In the
canonical pathway, complexes such as p50/RelA-IkBa
are induced by an IKK complex that requires IKKa,
IKKb and NEMO, whereas the non-canonical pathway
requires only IKKa and induces the partial degradation
of p100/RelB to p52/RelB.
It should be noted that in addition to the well-
characterized mechanisms of negative and positive
regulation of NF-kB described above, other pathways
involving different kinases, such as NF-kB-inducing
kinase (NIK) and IKKe, can also lead to NF-kB
activation through alternative pathways (Hayden and
Ghosh, 2004; Adli and Baldwin, 2006). In addition, a
variety of post-translational modiﬁcations of the NF-kB
subunits or signaling components can also modulate the
strength and duration of the NF-kB signal (Perkins,
2006). As described in this review, NF-kB and IKK
proteins are also associated with oncogenesis and cancer
therapy responses through a complex and dynamic set
of regulatory pathways.
Linking NF-jB with oncogenesis
The initial cloning of the NF-kB p50/p105 subunit
cDNA revealed homology to the cellular homolog
(c-Rel) of the oncoprotein (v-Rel) of the avian reticu-
loendotheliosis virus, suggesting a link between NF-kB
and oncogenesis. Subsequently, it was shown that the
NF-kB p52/p100 subunit encoded by the NFKB2 gene
undergoes structural alterations in certain T-cell lym-
phomas, chronic lymphocytic leukemias, myelomas and
B-cell lymphomas (see Courtois and Gilmore, 2006).
Similarly, the gene for the IkB family member Bcl-3
is found to be translocated and overexpressed in some
B-cell leukemias. In addition, c-rel gene ampliﬁcation is
detected in several types of B-cell lymphoma, whereas a
subset of Hodgkin’s lymphoma cases contain IkBa gene
mutations or deletions (Orlowski and Baldwin, 2002;
Courtois and Gilmore, 2006).
In addition to these genetic observations, gene
expression studies have identiﬁed NF-kB transcription
targets that are likely to promote the oncogenic
phenotype (see Figure 1). For example, gene proﬁling
has identiﬁed a subset of diffuse large B-cell lymphomas
(the activated B-cell-like tumors) that requires NF-kB
for growth and survival; in this case, the expression of
genes associated with this type of lymphoma is blocked
when NF-kB activity is inhibited (Lam et al., 2005).
Similarly, in murine ﬁbroblasts, oncogenic Ras expres-
sion regulates a set of approximately 25 genes in a
manner dependent on NF-kB activity (Hanson et al.,
2004). Interestingly, these studies also indicate that
the NF-kB-controlled gene sets in distinct oncogenic
settings are signiﬁcantly different. Nonetheless, cancer
relevant, NF-kB-dependent genes include those encod-
ing cytokines, chemokines, cyclin D1, matrix metallo-
proteinases and antiapoptotic proteins (Figure 1).
As described below, recent evidence has accumulated
from a large variety of human malignancies indicating a
role for NF-kB in promoting oncogenic conversion and
in facilitating later stage tumor properties such as
metastasis (Rayet and Ge´linas, 1999; Baldwin 2001;
Karin et al., 2002).
Cancer-associated mechanisms and NF-jB
Human cancer is a disease that stems from diverse
etiologies and that harbors distinct affected cell targets,
having therefore a very complex nature. Nevertheless,
Hanahan and Weinberg (2000) have outlined a number
of common features that override normal controls on
proliferation and homeostasis and which appear to be
associated with virtually all cancers. These shared
properties are intrinsic to the cancer cells, but also can
originate from signals that come from the surrounding
tumor microenvironment. These common, cancer-asso-
ciated mechanisms include the following: self-sufﬁciency
in growth and loss of growth inhibitory mechanisms;
suppression of apoptotic thresholds; enhanced angio-
genic properties; and the ability to invade local tissue
and metastasize to distant sites (reviewed by Hanahan
and Weinberg, 2000). Interestingly, all these cellular
processes are known to be affected in one way or
another by the NF-kB pathway (see below).
Growth and proliferation
The growth of cancer cells in an autonomous manner is
often controlled by altered expression of growth factors
or growth factor receptors, leading to cell proliferation.
A relatively common growth mechanism in epithelial
cancers is the upregulation of expression of members of
the epidermal growth factor (EGF) receptor (EGF-R)
family such as the EGF receptor or the Her-2/ErbB2
receptor. Additionally, growth factors such platelet-
derived growth factor (PDGF) and transforming growth
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Figure 1 Representation of NF-kB-dependent targets involved in
different aspects of oncogenesis. See text for further information.
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factor alpha (TGFa) are often expressed in cancers
and promote cell proliferation in an autocrine man-
ner (reviewed by Hanahan and Weinberg, 2000).
Nonetheless, cancer cell growth promotion can also
be stimulated by cancer-associated stromal cells or
recruited inﬂammatory cells through paracrine
mechanisms.
Another common mechanism that promotes the
growth of cancer cells is the presence of mutations in
proteins that regulate cell proliferation. Thus, activating
mutations in cellular RAS alleles lead to chronic
stimulation of signal-transduction pathways such as
extracellular signal-regulated protein kinase, phosphati-
dylinositol 3-kinase (PI3K)/Akt and RalGDS, which are
involved in cell growth and survival. Additionally,
cancer cell growth can be promoted by activating
mutations in transcription factors, such as b-catenin,
which controls expression of genes that stimulate
proliferation, such as cyclin D1 or c-myc. Furthermore,
resistance to growth inhibitory signals can be achieved
through mutations in tumor suppressor genes such as
Rb, APC, Arf or p53, or in receptors such as those for
TGFb (Hanahan and Weinberg, 2000).
Interestingly, NF-kB can promote cellular prolifera-
tion through regulation of speciﬁc target genes. For
example, NF-kB can promote Rb hyperphosphorylation
by binding and activating the cyclin D1 promoter
(Karin, 2006; Kim et al., 2006). Additionally, the IkB
homolog Bcl-3 in association with p52 homodimers has
also been found to transactivate potently the cyclin D1
gene (Westerheide et al., 2001). Furthermore, IKKa has
been proposed to play a role in cyclin D1 transcription
through a T-cell factor site in the promoter, via its
ability to control b-catenin phosphorylation (Albanese
et al., 2003). Consistent with a role for IKKa in
promoting cyclin D1 transcription, Karin et al. (2002)
have found that during mammary gland development
IKKa is required for RANK signaling and cyclin D1
expression. Other mechanisms whereby NF-kB may
potentiate cancer cell growth is through its reported
requirement for the upregulation of HIF-1a (Jung et al.,
2003) and its regulation of c-myc transcription (see
Baldwin 2001; Karin et al., 2002). Consistent with these
reports, tumor growth in several mouse xenograft
models is impaired when NF-kB is inhibited (see
Reuther et al., 1998; Baldwin, 2001; Karin et al., 2002).
Apoptosis evasion
Resistance to apoptosis is a common feature of cancer
cells and is associated with the increased expression of
antiapoptotic factors, such as Bcl-2 or Bcl-xL, or the
loss of expression, inactivation or mutation of proapop-
totic factors, such as Foxo3a or p53. For instance,
mutations in the tumor suppressor PTEN lead to the
activation of intracellular signaling pathways, which
suppress apoptosis via increased PI3K/Akt activity.
Relative to Akt, this Ser-Thr kinase is known to target
the phosphorylation of several factors associated with
regulating apoptosis (Downward, 2004). An additional
mechanism of suppression of cancer cell apoptosis can
be derived from the release of cytokines from the tumor
stroma. Importantly, expression of antiapoptotic factors
in tumor cells provides a strong mechanism to suppress
cancer therapy efﬁcacy (see below).
Interestingly, NF-kB directly regulates a potent
antiapoptotic pathway. Genes regulated by NF-kB that
suppress apoptosis, such as Bcl-2 and Bcl-xL (see
Figure 1), are often expressed in human cancers. Given
the strong association between NF-kB and the regula-
tion of apoptosis (Burstein and Duckett, 2003;
Kucharczak et al., 2003; Dutta et al., 2006), it is not
surprising that many studies suggest that NF-kB
controls the antiapoptotic mechanisms associated with
oncogenesis. Experiments revealed that induction of
expression of H-RasV12 in immortalized mouse ﬁbro-
blasts leads to cellular transformation but not to
apoptosis, and inhibition of NF-kB in H-RasV12-
transformed cells by the expression of a ‘super-repressor’
degradation-resistant form of IkBa (IkBa-SR) is asso-
ciated with high levels of apoptosis (Mayo et al., 1997;
Baldwin, 2001), indicating that NF-kB provides a
prosurvival function in the context of Ras-induced
oncogenesis. Consistent with this point, inhibition of
NF-kB in certain tumor cell lines leads to apoptotic cell
death (Karin et al., 2002; Kim et al., 2006). For instance,
proliferation and survival of Hodgkin/Reed–Sternberg
cells is blocked when NF-kB is inhibited by
IkBa expression (Bargou et al., 1997). Moreover,
inhibition of NF-kB in Hodgkin/Reed–Sternberg cells
leads to the loss of expression of antiapoptotic effectors
A1/Bﬂ-1, cellular-inhibitor of apoptosis 2 (c-IAP2),
tumor necrosis factor receptor-associated factor1
and Bcl-xL (Hinz et al., 2001). Finally, another
mechanism whereby NF-kB may block cell death is
through its ability to suppress persistent c-Jun NH2-
terminal kinase (JNK) activation and the generation of
reactive oxygen species (see Luo et al., 2005; Bubici
et al., 2006).
The NF-kB upstream regulatory pathway also plays a
role in preventing apoptosis. In that sense, Hu et al.
(2004) have shown that IKKb activation in breast
cancer cells promotes cell proliferation and suppres-
ses apoptotic potential through phosphorylation and
degradation of the proapoptotic factor Foxo3a.
Angiogenesis, invasion and metastasis
Tumor progression is determined by different mechan-
isms. Most tumors exhibit properties associated with
inducing and sustaining angiogenesis, a process that
appears to be required for tumor maintenance and
progression. Often associated with the appearance of
angiogenesis is the ability of tumor cells to invade local
tissues and subsequently to migrate systemically to
preferred sites (metastasis). The ability of tumor cells to
invade locally and to metastasize is also dependent on
suppression of apoptotic potential, on changes in the
expression of cell adhesion molecules and integrins,
and on changes in the expression of extracellular
proteases such as matrix metalloproteinase (MMP)-2
and MMP-9.
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An additional key mechanism in the progression of
many cancers is the epithelial-to-mesenchymal transi-
tion. While the differentiated epithelial phenotype is
typically characterized by the polarization of the cell
surface into apical and basolateral domains and by a
junctional complex that controls intercellular adhesion,
many cancers exhibit an alteration in this phenotype,
with progression to a metastatic phenotype (Thiery,
2002).
NF-kB appears to play a role in each of these
processes. In this regard, NF-kB has been reported to
promote both angiogenesis and metastasis in certain
tumor models, potentially through the regulation of
vascular endothelial growth factor (VEGF) and MMPs
(Figure 1) (see Baldwin, 2001; Karin et al., 2002). In
addition, expression of the super-repressor form of IkBa
in human melanoma and ovarian cancer cells correlates
with reduced VEGF and interleukin (IL)-8 expression
and blocks growth, angiogenesis and metastasis of
tumor xenografts (Huang et al., 2000b). Moreover,
NF-kB inhibition by overexpression of IkBb in lung
cancer cells suppressed their ability to form metastasis
(Jiang et al., 2001). It should be noted that these studies
often demonstrate that inhibition of NF-kB also causes
reduction of tumor growth, so that it is difﬁcult to
demonstrate absolutely that NF-kB directly controls
angiogenesis and metastasis. Finally, NF-kB has been
shown to mediate the epithelial–mesenchymal transition
(Huber et al., 2004a, b), although the exact mechanism is
unclear.
NF-jB in the tumor micro-environment
As described above, NF-kB- and IKK-controlled path-
ways appear to play key roles in cancer cell autonomous
phenotypes, but there is also evidence that NF-kB
functions in tumor-associated cells to affect oncogenic
mechanisms. Using IKKb ablation in myeloid cells in a
carcinogen/inﬂammation model for colorectal cancer,
Greten et al. (2004) showed that NF-kB controls the
ability of invading myeloid cells to produce cytokines,
which are involved in promoting tumor growth. In
another interesting study, NF-kB appears to mediate an
IL-1/nitric oxide paracrine growth loop involving
stromal ﬁbroblasts and pancreatic neoplastic cells
(Muerkoster et al., 2004).
Mechanisms of NF-jB activation in cancers
An outline of the regulatory pathways that target
NF-kB in oncogenesis is presented in Figure 2.
Activation by oncoproteins
Many oncoproteins can activate NF-kB (see Figure 2)
as measured through reporter assays or through analysis
of nuclear levels of NF-kB DNA-binding activity
(Baldwin, 2001; Karin et al., 2002). For instance,
NF-kB is activated by both Her-2/Neu (ErbB2) and
oncogenic H-Ras expression (Finco et al., 1997; Pianetti
et al., 2001). Interestingly, in immortalized murine
ﬁbroblasts, oncogenic H-Ras requires the NF-kB sub-
units RelA and c-Rel for efﬁcient cellular transforma-
tion (Hanson et al., 2004). In addition, activation of
NF-kB by oncogenic Ras was reported to involve the
IKK complex (Arsura et al., 2000; Figure 2). Another
oncoprotein shown to activate an NF-kB-dependent
reporter is Bcr-Abl, the fusion protein associated with
chronic myelogenous leukemia (CML) (Reuther et al.,
1998). Interestingly, Bcr-Abl-induced tumor growth is
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Figure 2 Pathways of activation of NF-kB by oncoproteins and
growth factors. Overexpression of EGF-R family members (EGFr
or ErbB2) by or ligand overexpression (EGF, TGFa, etc.), as well
expression of oncoproteins, such as Ras, Bcr-Abl, MALT1/c-IAP2
and Tax ultimately activate NF-kB through the canonical pathway
by targeting the IKK complex and leading to nuclear translocation
of RelA/p50 heterodimers. Nonetheless, whereas MALT1/c-IAP2
and Tax can directly activate IKK, EGF-R family receptors, Ras
and Bcr-Abl activate IKK indirectly through stimulation of cancer-
associated pathways, such as PI3K/Akt and MEKK1. Interest-
ingly, Ras can also be activated downstream of EGF-R family
receptors and Bcr-Abl. Both CK2 and Pin-1 can activate NF-kB
downstream of IKK. Whereas Pin-1 binds to RelA, releasing its
interaction with IkBa, CK2 promotes IkBa degradation. NF-kB
can also be activated by the non-canonical pathway in cancer. For
instance, NIK and STAT3 promote p100 processing by activating
IKKa, resulting in nuclear translocation of p52/RelB heterodimers.
Interestingly, the E3-ubiquitin ligase receptor bTRCP can activate
NF-kB both through the canonical and non-canonical pathways; it
is able to promote ubiquitination of both p100 and IkBa,
ultimately leading to p100 processing or IkBa degradation.
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blocked by IkBa-SR-mediated NF-kB inhibition (Re-
uther et al., 1998). In addition, Bcr-Abl-induced NF-kB
activation seems to involve the activation of the kinase
MEK kinase 1 (MEKK1) (Nawata et al., 2003) (see
Figure 2). Consistent with a role for NF-kB in Bcr-Abl-
associated malignancies, NF-kB was found to be
chronically active in CML and in Bcr-Abl-positive acute
lymphocytic leukemias (Kirchner et al., 2003; Munzert
et al., 2004; Cilloni et al., 2006). Another example of
activation of NF-kB by an oncoprotein is the mechan-
ism whereby the HTVL-1 Tax protein activates NF-kB;
that is, Tax can directly bind and activate the IKK
complex (Hiscott et al., 2006). In certain lymphomas,
NF-kB activation can also be triggered by the fusion
protein mucosa-associated lymphoid tissue (MALT)1/c-
IAP2; this protein activates NF-kB through ubiquitina-
tion of NEMO (Zhou et al., 2005a). A number of other
transforming proteins have been shown to activate NF-
kB, such as Vav (Palmby et al., 2004), Pim-2 (Hammer-
man et al., 2004) and B-Raf (Ikenoue et al., 2003).
Activation of NF-kB by oncogenic-associated pathways
Different signaling pathways known to play a role in
oncogenesis activate NF-kB. For example, PI3K/Akt-
dependent signaling activates NF-kB (Figure 2); this
occurs in a manner dependent on the relative levels of
the IKKa subunit (Gustin et al., 2004). In addition, Akt
is activated in primary acute myeloid leukemia and this
is associated with cell survival and NF-kB activation
(Grandage et al., 2005). Another example is the
activation of Akt in human melanoma, which leads to
NF-kB activation and tumor progression (Dhawan
et al., 2002). Moreover, PI3K/Akt-dependent signaling
is involved in the activation of NF-kB downstream of
Her-2/ErbB2 (Pianetti et al., 2001). Relative to other
signaling pathways, in a signiﬁcant number of lung
adenocarcinomas, Fas-associated death domain phos-
phorylation is associated with poor clinical outcome and
induces IKK-mediated NF-kB activation (Chen et al.,
2005). Interestingly, in pancreatic cancer cells, high
levels of expression of the E3-ubiquitin ligase receptor
beta-transducin repeat-containing protein 1 (bTRCP1)
is proposed to activate NF-kB (Muerkoster et al., 2005;
Figure 2). Finally, in breast cancer, CK2 was proposed
to induce NF-kB (Figure 2) and this effect was recently
proposed to involve the upregulation of the IKKe
subunit (Eddy et al., 2005).
Activation downstream of growth factors and growth
factor receptors
Growth factors play an important role in promoting
oncogenesis; thus, it is not surprising that certain growth
factors or expression of growth factor receptors can
activate NF-kB (Figure 2). For example, in certain cell
types, NF-kB can be activated by EGF (Biswas et al.,
2000), although the mechanism associated with this
activation is poorly characterized. Sitcheran et al. (2005)
have shown that EGF can induce recruitment of RelA
to the excitatory amino-acid transporter (EAAT)2/
glutamate transporter promoter through a mechanism
independent of IkB degradation. Moreover, NF-kB
is activated by the EGF-R family member Her-2/
ErbB2 (Pianetti et al., 2001), and there appears to be a
speciﬁc set of genes controlled by NF-kB downstream of
Her-2/ErbB2 (Merkhofer E and Baldwin AS, unpu-
blished). NF-kB activation can also be induced by the
growth factor PDGF, leading simultaneously to cell
proliferation by induction of c-myc transcription and
to increased survival by suppression of apoptosis
(Romashkova and Makarov, 1999). Finally, in human
mast cells, the NF-kB pathway can also be induced by
constitutively activated c-Kit receptors, resulting in the
upregulation of cyclin D3 expression and cell cycle
progression (Tanaka et al., 2005).
Other mechanisms for the activation of NF-kB in cancer
The proinﬂammatory cytokine IL-6 can act as a survival
factor for different cancer cells and induces signaling
through the signal transducers and activators of
transcription (STAT) proteins. Interestingly, constitu-
tively active STAT3 is found in IL-6-dependent multiple
myeloma cell lines that are resistant to apoptosis
(Catlett-Falcone et al., 1999). In addition, STAT3 levels
are elevated in a number of human cancers, including
breast cancer, prostate cancer, head and neck cancers,
and hematologic malignancies (Bowman et al., 2000).
Furthermore, STAT3 induces cellular transformation
in vitro and tumor formation in nude mice (Bromberg
et al., 1999). When acetylated, STAT3 promotes
p100 processing to p52 and thereby activates NF-kB
(Nadiminty et al., 2006, Figure 2). Therefore, the
regulation of NF-kB downstream of STAT3 activation
in IL-6-producing cancers should be considered as a
relevant oncogenic event.
Another unexpected mechanism to activate NF-kB in
cancer has been proposed to involve the prolyl
isomerase Pin1. Ryo et al. (2003) showed that Pin1
expression in human breast cancer samples correlates
with nuclear levels of RelA. This study suggests that
Pin1 binds to RelA, inhibiting interaction with IkB
and resulting in increased nuclear accumulation of this
NF-kB subunit (Figure 2). Consistently, downregulation
of Pin1 with small interfering RNA in two breast cancer
cell lines suppressed NF-kB activity.
Inhibition of NF-jB by tumor suppressors
NF-kB activity is clearly modulated by oncoproteins,
but evidence has also been presented that NF-kB
activation can be blocked by certain tumor suppressors.
One example is the tumor suppressor Arf, which has
been shown to inhibit NF-kB through a mechanism
involving ATR- and Chk1-induced phosphorylation of
RelA (Rocha et al., 2005). Additionally, the tumor
suppressor CYLD blocks NF-kB and Bcl-3 activation
through its deubiquitinating activity (Kovalenko et al.,
2003; Trompouki et al., 2003; Massoumi et al., 2006).
Moreover, the tumor suppressor menin, which is
mutated/deleted in parathyroid tumors, was reported
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to bind and suppress NF-kB activation (Heppner et al.,
2001). Regarding the tumor suppressor p53, it was
reported that p53 generally inhibits NF-kB function,
and vice versa (Webster and Perkins, 1999); however,
more complex relationships between p53 and NF-kB
have emerged (see below).
NF-jB in human cancers
NF-kB activation as measured by nuclear accumulation
or by increased DNA-binding activity has been observed
in a wide variety of solid tumors and hematologic
malignancies (see Figure 3). Below we discuss a few
examples of NF-kB activation and its involvement in
different cancers.
Breast cancer
Breast cancers are phenotypically heterogeneous, pre-
sently classiﬁed into six subtypes based on gene
expression proﬁling (Ramaswamy and Perou, 2003).
Nonetheless, different studies indicate that NF-kB is
activated in breast cancer cells, where it affects cell
proliferation, suppresses apoptosis as well as promotes
anchorage-independent growth. Indeed, a variety of
breast cancer cell lines displays increased NF-kB DNA-
binding activity (Nakshatri et al., 1997). However, the
classic NF-kB complex composed of p50/RelA hetero-
dimers is detected only in a minority of breast cancers
(Cogswell et al., 2000). Consistent with this, the RelA
subunit was detected as nuclear in approximately 16%
of primary breast cancers. On the other hand, Biswas
et al. (2004) reported that the p50/RelA heterodimer is
activated in the majority (86%) of estrogen receptor
(ER)-negative, ErbB2/Her2-positive breast tumors.
However, since elevated ErbB2 expression occurs in
approximately 20–25% of breast tumors, the above
results suggest that the activation of RelA is not widely
prevalent in primary breast tumors but may be
associated more with distinct subtypes (i.e., Her2
positive/ER negative). In addition, these results also
suggest that it is the loss of ER and the expression of
ErbB2 that strongly activates the binding potential of
the p50/RelA heterodimer. Indeed, whereas Her2/ErbB2
activates NF-kB by a mechanism that involves the
PI3K/Akt pathway and utilizes calpain to degrade
IkBa (Pianetti et al., 2001), ER has been shown to
regulate NF-kB negatively by a variety of mechanisms
(Kalaitzidis and Gilmore, 2005).
Interestingly, other NF-kB family members have been
implicated in breast cancer. For example, transgenic
mice with mammary cell-speciﬁc c-Rel expression
develop mammary tumors, albeit with a very long
latency (Romieu-Mourez et al., 2002). Moreover,
Cogswell et al. (2000) noted, in approximately 40%
of breast tumors, an increased binding potential of
p50- and p52-containing complexes with an increased
expression of Bcl-3. Additionally, it was reported that
enhanced DNA-binding activity associated with the p50
NF-kB subunit is associated with ER-positive breast
cancers destined for early relapse despite adjuvant
endocrine therapy with tamoxifen, suggesting an in-
volvement of this aspect of the NF-kB pathway in
endocrine-resistant breast cancer (Zhou et al., 2005b).
Recently, Eddy et al. (2005) provided evidence that
NF-kB activation in breast cancer cell lines is associated
with aberrant expression of the IKKe subunit, and
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Figure 3 Constitutive NF-kB activation in human cancers.
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elevated expression of IKKe was detected in 4/6 primary
tumor samples. Interestingly, we have recently found
that, in ceratin cancer cells, IKKe can induce the
phosphorylation of RelA at Ser-536 (Adli and Baldwin,
2006). These results raise the possibility that breast
tumor subtypes exhibit different forms of NF-kB
activation, some associated with enhanced p50/RelA
DNA binding, some with enhanced p50 or p52 DNA-
binding activity, some with enhanced c-Rel expression,
and some with increased Ser-536 phosphorylation of
RelA.
Melanoma and NF-kB
Melanoma is a skin cancer that originates in melano-
cytes and which progresses from pigmented lesions
called benign nevi to dysplastic nevi. The disease can
then progress to in situ melanoma followed by the
potential for invasive melanoma. Invasive melanoma is
highly resistant to standard forms of cancer therapy (for
a review, see Ueda and Richmond, 2006). Based on the
fact that several NF-kB-regulated chemokines are
constitutively expressed in human melanoma (Mrowietz
et al., 1999; Singh et al., 1999; Ueda and Richmond,
2006), it has been proposed that NF-kB plays an
important role in melanoma. The role for these
chemokines is thought to be at the level of enhancement
of growth and survival through autocrine and paracrine
mechanisms. Consistent with this, inhibition of IL-8 (an
NF-kB target) through the use of neutralizing anti-
bodies inhibits tumor angiogenesis in xenograft models
(Huang et al., 2002). In addition, suppression of NF-kB
activation by expression of the IkBa super-repressor can
block melanoma xenograft growth, angiogenesis and
metastasis (Huang et al., 2000a). Interestingly, the
activation of NF-kB in melanoma can be mediated by
NIK, a regulator of the non-canonical pathway of
NF-kB activation (Dhawan and Richmond, 2002).
Other mechanisms associated with NF-kB activation
in melanoma have been proposed to involve loss of p16,
signaling downstream of N-Ras and B-raf, Akt activa-
tion associated with PTEN loss, and autocrine/paracrine
mechanisms associated with chemokines and G-coupled
protein receptors or with growth factors such as EGF
(Ueda and Richmond, 2006).
NF-kB and pancreatic cancer
Pancreatic ductal adenocarcinoma is a fatal disease,
affecting about 30 000 people per year in the United
States. Pancreatic cancer is associated with inﬂamma-
tion either through pancreatitis or through Helicobacter
pylori positivity (Garcea et al., 2005). In a variety of
pancreatic cancer cell lines, but not in immortalized
pancreatic epithelial cells, NF-kB was found to be
constitutively activated. Activation of NF-kB also has
been observed in animal models for pancreatic cancer
and in human tissue from pancreatic tumors (Wang
et al., 1999c; Liptay et al., 2003; Garcea et al., 2005).
Using cell lines and xenografts, it appears that NF-kB
promotes proliferation and suppresses apoptosis in these
cancer cells (Liptay et al., 2003). Inhibition of NF-kB
via super-repressor IkBa expression blocks angiogenesis
and metastasis in human cancer-derived xenograft
tumors (Fujioka et al., 2003). Mechanisms of NF-kB
activation in pancreatic cancer appear to involve K-Ras
and Akt activation, as well as Notch-1 signaling, nuclear
glycogen synthase kinase-3b, and Vav1 (Wang et al.,
1999c, 2006; Asano et al., 2004; Fernandez-Zapico et al.,
2005; Ougolkov et al., 2005). Additionally, it has been
reported that autocrine production of IL-1a regulates
NF-kB activation in pancreatic cancer cells (Niu et al.,
2004). NF-kB-regulated gene targets that encode pro-
teins potentially relevant to the maintenance and
invasion of pancreatic cancer cells are proposed to be
GADD45a and urokinase-type plasminogen activator
(Wang et al., 1999b; Schneider et al., 2006).
NF-kB in hematologic malignancies
In addition to the observed NF-kB activity in solid
tumors, there is widespread observation of NF-kB
activation in hematological malignancies (see Figure 3).
For example, NF-kB activation and increased IKK
activity are found in blasts and stem cells associated
with acute myelogenous leukemia (AML) (Baumgartner
et al., 2002). Consistent with this, NF-kB activation is
detected in the bone marrow of patients with myelo-
dysplastic syndrome (Braun et al., 2006), which is
considered a precursor disease of AML. NF-kB is also
activated in childhood acute lymphoblastic leukemia
(Kordes et al., 2000), Hodgkin–Reed–Sternberg cells
(Bargou et al., 1997), HTLV-1-positive leukemias
(Hiscott et al., 2006), B-cell chronic lymphocytic
leukemia (Furman et al., 2000; Zaninoni et al., 2003)
and in primary blasts of CML (Kirchner et al., 2003). In
addition, NF-kB-dependent gene transcription is a
hallmark of the activated B-cell-like subset of diffuse
large B-cell leukemia (Lam et al., 2005; Ngo et al., 2006).
Finally, NF-kB activation is also associated with multi-
ple myeloma (Ni et al., 2001), where it seems to play a
crucial role. The importance of NF-kB in multiple
myeloma is suggested from its involvement downstream
of CD40, the tumor necrosis factor (TNF) receptor
family member that is expressed in a variety of B-cell
malignancies and which is associated with multiple
myeloma homing. Consistent with this, monoclonal
antibodies to CD40 block CD40L-induced NF-kB
activation as well as IL-6 and VEGF secretion in co-
cultures of multiple myeloma cells and bone marrow-
derived stromal cells (Tai et al., 2005). Interestingly,
multiple myeloma is currently treated with compounds
that can block NF-kB activation (Mitsiades et al.,
2002a) (see below).
Localized inﬂammation promotes oncogenesis
Inﬂammation is the ﬁrst host response to infection or
tissue injury and is mediated by the innate immune
system. It involves activation and directed migration of
leukocytes (neutrophils, monocytes and eosinophils)
from the venous system to sites of damage. Recruitment
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of these inﬂammatory cells to sites of tissue injury is
mediated by a family of chemotactic cytokines, named
chemokines, which possess a relatively high degree of
speciﬁcity for chemoattraction of speciﬁc leukocyte
populations. These inﬂammatory cells then secrete
growth factors and cytokines and thereby promote cell
proliferation and local invasive properties at the
inﬂammatory site. Nonetheless, these effects would
not, on their own, be expected to generate oncogenic
events because normal inﬂammation is usually self-
limiting; however, persistence of the initiating factors or
a failure of mechanisms required for resolving the
inﬂammatory response can lead to chronic inﬂamma-
tion, which can then promote oncogenesis (Coussens
and Werb, 2002).
Indeed, chronic inﬂammation is suspected to be an
important player in the development of a number of
cancers (e.g., pancreatitis with pancreatic cancer,
hepatitis with liver cancer, etc.) and a link has been
established between inﬂammatory bowel disease and
colorectal cancer. In fact, there is an approximately
10-fold increased risk for developing colorectal cancer in
patients who have colitis, and the risk increases
signiﬁcantly with the duration and extent of colitis
(reviewed by Clevers, 2004). In addition, recent evidence
indicates a signiﬁcant role for innate immune cell
involvement in colon cancer development (Balkwill
et al., 2005). Additional evidence for the involvement
of inﬂammation in promoting cancer is provided by
clinical studies that correlated poor clinical outcome
with tumor inﬁltration by immune and inﬂammatory
cells (Coussens and Werb, 2002) and from studies
showing reduced cancer incidence in patients under-
going treatment with anti-inﬂammatory drugs.
Although chronic inﬂammatory diseases are able to
promote oncogenesis, tumor cells themselves produce
various cytokines and chemokines that attract leuko-
cytes leading to an inﬂammatory response. This
inﬂammatory component of developing neoplasms can
then function to promote oncogenic progression. In that
sense, Sparmann and Bar-Sagi (2004) demonstrated that
oncogenic Ras expression leads to the upregulation of
the chemokine IL-8, which then functions to promote
tumor-associated inﬂammation, angiogenesis and tumor
growth. In this study, inhibition of IL-8 with a
neutralizing antibody blocked tumor cell growth.
Additionally, the IL-8 antibody reduced the recruitment
of neutrophils and macrophages into the derived tumors
and reduced the recruitment of endothelial cells leading
to decreased angiogenesis. This study demonstrates the
existence of a regulatory cascade initiating with onco-
protein expression, leading to the upregulation of a
proinﬂammatory cytokine, which recruits key inﬂam-
matory cells to promote tumorigenesis.
Since IL-8 is a target of NF-kB, it is likely that the
ability of Ras to activate IL-8 gene expression and
subsequent neutrophil recruitment is mediated through
NF-kB (see Figures 1 and 2). In addition, other
cytokines involved in the potentiation of inﬂamma-
tion-based cancers, such as cyclooxygenase (Cox)-2,
TNFa and IL-1 (Coussens and Werb, 2002; Clevers,
2004), can also be regulated by NF-kB (Figure 1).
Indeed, others have suggested that NF-kB represents a
causal link between inﬂammation and cancer (Greten
et al., 2004; Pikarsky et al., 2004, see below).
Roles for NF-jB in inﬂammation-associated cancers
Consistent with the important role played by NF-kB in
both innate and acquired immunity, recent published
data directly implicate NF-kB activation as a key
component in inﬂammation-based cancer progression.
Greten et al. (2004) applied the IKKb conditional
knockout model to test the role of the NF-kB activation
pathway in controlling tumorigenesis in a colitis-
associated model for cancer. Deletion of IKKb in
intestinal epithelial cells did not affect tumor size in
this model, but dramatically reduced tumor number.
The reduction in tumor number was explained by
strongly enhanced apoptosis in the DNA-damaged
intestinal target cells, consistent with a role of NF-kB
in suppressing apoptotic potential. Importantly, in this
model, the tumor-associated inﬂammation component
was not reduced. These data argue that NF-kB
activation is important in the early stages of DNA-
damaged induced tumorigenesis (as an antiapoptotic
mediator), but not in the prominent growth phase of
tumorigenesis. Nonetheless, Greten et al. (2004) went on
to show that deletion of IKKb in myeloid cells does not
affect tumor number, but leads to a signiﬁcant reduction
in tumor size and to a reduction in tumor-associated
proinﬂammatory cytokine levels that are likely to serve
as tumor growth factors. This result is consistent with
the importance of NF-kB in promoting myeloid cell
recruitment and inﬂammatory gene expression as part of
the inﬂammatory phase of oncogenesis.
Conversely, a different study suggested that NF-kB
does not play a role in the early inﬂammation-associated
neoplastic growth, but functions to suppress apoptosis
and to allow malignancy to progress (Pikarsky et al.,
2004). In this study, which utilized a mouse model of
spontaneous hepatitis followed by hepatocellular carci-
noma, inhibition of NF-kB in hepatocytes through
regulatable IkBa super-repressor expression did not
block hepatitis or the earliest stages of neoplasia;
however, inhibition of NF-kB at later stages (either
through IkBa expression or through TNF antibodies)
induced apoptosis and blocked progression to hepato-
cellular carcinoma. In a related study, Maeda et al.
(2005) showed that, although loss of IKKb in hepato-
cytes actually promotes chemical-induced hepato-
carcinogenesis through a compensatory mechanism
downstream of JNK-mediated cell death, knockout of
IKKb in hemopoietic-derived Kupffer cells suppressed
hepatocarcinogenesis, indicating that NF-kB expression
in these cells is crucial for the inﬂammation-mediated
neoplastic growth.
A role for NF-kB in inﬂammation-associated cancer
has also been presented by less direct, but highly
suggestive evidence. For example, NF-kB activation is
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suggested to promote neoplastic progression in Barrett’s
esophagus, a disease associated with inﬂammation. It is
proposed that this is mediated through the ability of
NF-kB to regulate Cox-2 and IL-8 gene expression. In
addition, Jung et al. (2003) reported that IL-1b induces
HIF-1a gene expression through a mechanism involving
the induction of PGE2 through the NF-kB-dependent
upregulation of Cox-2. These studies suggest a direct
mechanism whereby NF-kB-regulated cytokines such as
IL-1b, IL-8 or Cox-2 promote oncogenesis.
The above-discussed evidence of a role for NF-kB in
controlling inﬂammation-based oncogenesis suggests
that inhibitors of this transcription factor are likely to
serve as key components in the prevention of many
cancers. Thus, studies demonstrating the ability of non-
steroid anti-inﬂammatory compounds to suppress the
development of some cancers are consistent with this
hypothesis (see below).
Approaches to blocking NF-jB for cancer therapy
Given the importance of the NF-kB pathway in
oncogenesis, there are a growing number of transla-
tional/clinical studies in which NF-kB activity in cancer
cells is inhibited by different compounds. These include
compounds that have already been approved for use in
therapy, compounds that are undergoing clinical trials
and compounds that show therapeutic promise in
preliminary studies (see below). In summary, extensive
evidence demonstrates that compounds which block
NF-kB activation can serve to block cancer cell growth
(Baldwin, 2001; Yamamoto and Gaynor, 2001; Karin
et al., 2002; Gilmore and Herscovitch, 2006).
Proteasome inhibitors
The proteasome regulates the turnover of a range of
different proteins within the cell by promoting degrada-
tion of ubiquitinated proteins, including IkB family
members. Therefore, proteasome inhibitors, which
prevent degradation of IkB proteins, have been exten-
sively used in cancer studies to block NF-kB activity.
For example, proteasome inhibition in adult T-cell
leukemia primary cells correlates with stabilized IkBa
and consequently inhibits NF-kB; this leads to impaired
cell growth and induced apoptosis (Nasr et al., 2005).
Probably a more clinically relevant example is the use of
proteasome inhibitors for the treatment of multiple
myeloma, which is considered a disease dependent on
NF-kB activation (Richardson et al., 2004). A highly
speciﬁc inhibitor of the proteasome is bortezomib/
PS-341/VELCADE, which is currently approved for
the treatment of multiple myeloma (Richardson et al.,
2004). A newly developed proteasome inhibitor, NPI-
0052, with properties distinct from bortezomib, also
induces the death of multiple myeloma cells (Chauhan
et al., 2005).
Although proteasome inhibitors have shown efﬁcacy
in the treatment of multiple myeloma, evidence for
clinical efﬁcacy for the treatment of solid tumors is
missing. However, proteasome inhibitors have shown
efﬁcacy in a number of preclinical models for solids
tumors and these responses are typically associated with
the inhibition of NF-kB and of NF-kB-dependent gene
expression. For example, a recent study showed that the
proteasome inhibitor PS-341 causes growth arrest and
apoptosis in human glioblastoma cell lines and tumor
explants (Yin et al., 2005), which is correlated with the
inhibition of NF-kB and downregulation of Bcl-2 and
Bcl-xL. In addition, proteasome inhibitors have shown
antitumor activity in models of breast, lung, colon,
bladder, ovary, pancreas and prostate cancers (reviewed
by Yin et al., 2005).
Although bortezomib/PS-341/VELCADE can block
NF-kB activation, it is unclear whether the primary
mode of action of this compound in multiple myeloma
and other malignancies is solely (or even partially)
dependent on its ability to inhibit NF-kB activation. In
this regard, in addition to its effects on NF-kB,
bortezomib has been reported to block JNK activation
through the upregulation of MAP kinase phosphatase-1
(Small et al., 2004) and to modulate Ca2þ /mitochondrial
function (Landowski et al., 2005). Additionally, it has
been reported that bortezomib initiates tumor cell-
selective apoptosis that is correlated with the induction
of the proapoptotic gene encoding the BH3-only protein
Noxa (Fernandez et al., 2005). In that study, protea-
some inhibition did not correlate with a generalized
inhibitory effect on NF-kB.
Thalidomide and analogs
Thalidomide is an anti-inﬂammatory drug that can
block NF-kB activity and has been shown to have
antioncogenic properties. Thalidomide and immuno-
modulatory thalidomide analogs have shown acti-
vity against relapsed or refractory multiple myeloma
(Rajkumar, 2003). For example, thalidomide was
evaluated with dexamethasone in earlier stage disease
and yielded response rates in the range of 70%.
Treatment of smoldering/indolent disease with single-
agent thalidomide yielded overall response rates in the
35% range (Rajkumar, 2003). There is evidence that
thalidomide and its analogs have direct impact on
multiple myeloma cells through the induction of
apoptosis and growth arrest. Importantly, thalidomide
was shown to inhibit NF-kB in these cells (Mitsiades
et al., 2002b). These results are consistent with our
earlier report that thalidomide blocks NF-kB activation
via suppression of IKK activity (Keifer et al., 2001).
Non-steroid anti-inﬂammatory drugs
While non-steroid anti-inﬂammatory drugs (NSAIDs)
are described generally as inhibitors of Cox-2 activity, it
is also possible that these compounds target NF-kB
activity. In fact, it was recently shown in vitro that the
Cox-2 inhibitor celecoxib inhibits NF-kB activation
induced by TNF through a mechanism that involved
suppression of IKK and Akt activation (Shishodia et al.,
2004). This same group showed that NSAIDs exhibit
differing strengths in their ability to suppress NF-kB
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activity and NF-kB-dependent gene expression, with
celecoxib as the most potent inhibitor and aspirin the
weakest (Takada et al., 2004). Interestingly, celecoxib
can induce apoptosis in a variety of leukemia cell lines
in a manner that is correlated with the suppression
of NF-kB activation (Subhashini et al., 2005). Sulfasa-
lazine, another NSAID that blocks NF-kB activation,
has been shown to inhibit growth and induce apoptosis
in both glioblastoma cell lines and primary cultures to
a similar level as obtained by the expression of a
degradation-resistant super-repressor form of IkBa
(Robe et al., 2004). Thus, it is possible that NSAIDs
might prevent cancer progression through the inhibition
of NF-kB.
Curcumin, IKK inhibitors, arsenic and parthenolide
A range of compounds with NF-kB inhibitory activity
has also been shown to have antitumor or antiangio-
genic potential as studied on tumor cell lines and derived
xenografts. One of the more extensively studied com-
pounds in this group is curcumin, a diferuloylmethane
derived from turmeric, which has been shown to
suppress NF-kB activation and NF-kB-dependent gene
expression. Previous studies had indicated that curcu-
min has strong antitumor effects on AML and prostate
cancer cell lines (Mukhopadhyay et al., 2001; Anto
et al., 2002). Recently, curcumin has been shown to
induce growth arrest and apoptosis in mantle cell
lymphoma cell lines (Shishodia et al., 2005), where it
suppressed the expression of the genes encoding cyclin
D1, Bcl-2 and Bcl-xL, all known NF-kB target genes.
Another group of NF-kB inhibitory compounds are
small-molecule inhibitors of the IKK kinases. The IKK
inhibitors BAY 11-7082 and AS602868 have shown
efﬁcacy in leukemia models via their ability to induce
increased apoptosis (Frelin et al., 2005; Garcia et al.,
2005). Another small-molecule inhibitor of IKK (PS-
1145) was found to be selectively toxic for subtypes of
diffuse large B-cell lymphoma cells that are associated
with NF-kB activation (Lam et al., 2005). This
compound was shown to lead to the downregulation
of a set of NF-kB-dependent genes.
Additionally, arsenic, which is used for the treatment
of acute promyelocytic leukemia, was shown to inhibit
constitutive NF-kB/IKK activity and NF-kB target
genes in Hodgkin/Reed–Sternberg cell lines, and to
induce apoptosis in these cells (Mathas et al., 2003).
Introduced expression of RelA overcame the arsenic-
induced cell death, suggesting the relevance of NF-kB
as the target for arsenic (Mathas et al., 2003). Another
NF-kB inhibitor, the natural product parthenolide, has
also shown efﬁcacy against human AML stem and
progenitor cells (Guzman et al., 2005), and cholangio-
carcinoma cells (Kim et al., 2005b). Finally, a number of
well-established dietary chemopreventive compounds
have been shown to inhibit NF-kB (Yamamoto and
Gaynor, 2001). It should be noted that a caution with
some of these studies is that the therapeutic effects
of certain inhibitors may involve the regulation of non-
NF-kB targets.
NF-jB activation and cancer therapy
Evidence was presented in the mid-1990s that DNA-
damaging and stress-inducing agents activate NF-kB
(see Baldwin, 2001; Yamamoto and Gaynor, 2001;
Karin et al., 2002; Nakanishi and Toi, 2005). For
example, NF-kB activation is seen in response to the
chemotherapeutic compound daunorubicin and to
irradiation (Wang et al., 1996). Inhibition of NF-kB
by expression of the super-repressor form of IkBa
strongly enhanced the apoptotic efﬁcacy of daunorubi-
cin and of radiation (Wang et al., 1996). The topoi-
somerase I inhibitor CPT-11 can activate NF-kB in
experimental colorectal tumors and the administration
of adenovirally expressed super-repressor IkBa or the
proteasome inhibitor PS-341 inhibits NF-kB activation
and signiﬁcantly enhances the apoptotic response of the
tumor to CPT-11 (Wang et al., 1999a; Cusack et al.,
2001). Thus, a model was proposed whereby activation
of NF-kB in response to chemotherapies and to
radiation functions to suppress the cancer therapy’s
apoptotic potential (Baldwin, 2001) (see Figure 4).
A number of other reports using a variety of
chemotherapies and a variety of approaches to blocking
NF-kB support this model (Baldwin, 2001; Yamamoto
and Gaynor, 2001; Karin et al., 2002; Nakanishi
and Toi, 2005). The recent review by Nakanishi and
Toi (2005) provides a thorough outline of different
chemotherapies that activate NF-kB and of compounds
that can be used to block NF-kB activation to promote
cancer therapy efﬁcacy. For example, a study analysing
NF-kB inhibition in association with radiation indicates
that NF-kB activation in experimental colorectal tumors
leads to radiation resistance (Russo et al., 2001). In
addition, a more recent report indicates that NF-kB
inhibition sensitizes cancer cells to tumor-necrosis factor-
related apoptosis-inducing ligand-induced apoptosis
through the sustained activation of JNK (Nakshatri
et al., 2004). Based on these studies, clinical trials
utilizing certain chemotherapies in conjunction with
NF-kB inhibitors (proteasome inhibitors, thalidomide,
etc.) are presently underway.
While the evidence that NF-kB often functions in an
antiapoptotic manner downstream of its activation by
chemotherapy or radiation is strong, recent data
indicate that NF-kB activation by certain non-tradi-
tional cancer therapies in certain cell types can also
function in a proapoptotic manner (see Figure 4). For
example, apoptosis induced by the retinoid 3-Cl-AHPC
was reported to require NF-kB activation (Farhana
et al., 2005). Exposure of cells to this compound blocked
the expression of X-linked inhibitor of apoptosis, Bcl-xL
and c-IAP1, and enhanced the expression of proapop-
totic death receptors DR4 and DR5 as well as Fas. In a
similar study, the retinoid CD437 was shown to activate
NF-kB in DU145 prostate cancer cells and to contribute
to the induction of apoptosis through the upregulation
of the death receptors DR4 and DR5 (Jin et al., 2005).
In addition, aspirin and UV-C induce apoptosis through
a mechanism that drives RelA to the nucleolus, leading
to an inability to activate NF-kB-dependent genes
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(Stark and Dunlop, 2005). Under these conditions,
NF-kB inhibition would be counterintuitive as a cancer
therapy.
Nonetheless, which signaling events ultimately deter-
mine whether NF-kB activation will lead to a pro- or
antiapoptotic response are presently unclear. For
example, Campbell et al. (2004) found that NF-kB
activation induced by etoposide in U-2 OS osteosarco-
ma cells leads to the traditional antiapoptotic response
and is associated with the activation of Bcl-xL gene
expression. On the other hand, NF-kB activation by
doxorubicin and daunorubicin in the same cells pro-
motes cell death and leads to the NF-kB-mediated
repression of antiapoptotic genes such as Bcl-xL.
Interestingly, it was found that daunorubicin induced
the association of RelA with the histone deacetylases 1,
2 and 3, consistent with the role for NF-kB in repressing
gene expression downstream of responses to that
chemotherapy. A similar report indicated that doxor-
ubicin-induced NF-kB is deﬁcient in transcriptional
activity, which is associated with reduced phosphoryla-
tion and acetylation of RelA (Ho et al., 2005). In
addition, NF-kB activation by doxorubicin in four
colorectal cancer cells is required for the anticancer
efﬁcacy of the drug (Ashikawa et al., 2004). However,
there are other papers where doxorubicin-induced cell
death is inhibited by NF-kB activation (see Baldwin,
2001; Nakanishi and Toi, 2005). The basis of these
conﬂicting results is not known.
It is reasonable to speculate that the pro- vs
antiapoptotic activity of NF-kB is determined by the
phenotypic proﬁle of the tumor in combination with the
speciﬁc cancer therapy (Figure 4). In this respect, the
activation of NF-kB itself by the relevant cancer therapy
is not likely to be the determining outcome on gene
expression. Presumably, modiﬁcation of NF-kB sub-
units (or lack thereof) related to the regulatory status of
the cancer will then determine whether NF-kB functions
in the anti- or proapoptotic response (Figure 4). In this
sense, this antagonic behavior of chemotherapy-induced
NF-kB in different cancer settings clearly shows the
importance of individualized cancer therapy, probably
based on a knowledge of the molecular phenotype of a
given cancer.
NF-jB as a tumor suppressor
While there is solid evidence that NF-kB can function in
a pro-oncogenic manner, other experimentation indi-
cates that NF-kB can, under certain circumstances,
function in a tumor suppressor role (see Perkins, 2004;
Shishodia and Aggarwal, 2004). For example, one
report demonstrated that inhibition of NF-kB in skin
leads to oncogenic potential and potentiates H-Ras-
induced transformation (Dajee et al., 2003). One
mechanism to explain this concept is that inhibition of
NF-kB in the skin leads to JNK activation (Zhang et al.,
2004), a ﬁnding consistent with several reports that
NF-kB activation suppresses the phosphorylation and
activation of JNK.
Similar questions regarding the oncogenic potential of
NF-kB arise with the consideration that NF-kB appears
to function downstream of the tumor suppressor p53.
Ryan et al. (2000) have presented evidence that NF-kB
activation is required downstream of p53 in order for
this tumor suppressor to induce apoptosis. However,
other experimentation indicates that NF-kB/IKK acti-
vation can destabilize p53 (Tergaonkar et al., 2002).
Similar to these ﬁndings, it has been shown recently that
Bcl-3/p52 activation suppresses p53 activation through
upregulated Hdm2 gene expression (Kashatus et al.,
2006). Thus, the interplay between NF-kB/IKK signal-
ing and p53 function is complex and needs further
exploration.
Overall, these ﬁndings suggest that NF-kB can
function, under certain conditions, as a tumor suppressor.
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Figure 4 Targeting the NF-kB pathway as primary or adjuvant
therapy in cancer. NF-kB is activated by standard chemothe-
rapeutic agents and by retinoids, either by the DNA damage
response induced by many of these agents or by other pathways
that will directly activate the IKK kinase complex. In the nucleus,
NF-kB can mediate either a pro- or antiapoptotic transcriptional
response, apparently depending on the cancer cell regulatory
environment. Targeted inhibition of the NF-kB pathway at
different levels (directed towards the upstream pathways, IKK or
the proteasome-dependent activation of NF-BB has proven
beneﬁcial both as stand-alone therapy as well as in combination
with other therapeutic agents.
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The potential role of NF-kB as a tumor suppressor has
been reviewed elsewhere (Perkins, 2004; Shishodia and
Aggarwal, 2004).
Concluding remarks
An enormous amount of data strongly implicates
transcription factor NF-kB in a variety of oncogenic
mechanisms. Additionally, there is compelling evidence
for an important role for NF-kB in modulating cancer
therapy efﬁcacy. A major challenge is to distinguish the
situations where NF-kB functions pro-oncogenically/
antiapoptotically from those where it may function as a
tumor suppressor and a proapoptotic factor. In this
regard, it is important to identify the molecular
mechanisms that dictate these outcomes. A second
challenge is to bring rational inhibitors of NF-kB or
its upstream regulatory pathways to clinical cancer
therapy in a manner consistent with an antiapoptotic/
proproliferation role, either as stand-alone therapies or
as adjuvants with existing or new therapies.
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